Analytical Data
-
基因名
C1ra
- Application
-
别名
C1ra；C1r；Complement C1r-A subcomponent
-
种属
Mouse
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8CG16
-
表达区间
17-707aa
-
氨基酸序列
SIYLPQKLYGEVTSPLYPKPYPSDLETTTVITVPMGYRVKLVFWQFDVEPSEGCFYDYVKISADKQTLGRFCGQLDSPLGNPPGSKEFMSQGNKMLLTFHTDFSNEENGTIMFYKGFLAYYQAVDLDECASQPNSVEEGLQPRCQHLCHNYVGGYFCSCHPGYELQKDGQSCQAECSSELYTEPSGYVSSLEYPQPYPPDLRCNYSIRVERGLTVHLKFLDPFEIDDHQQVHCPYDQLQIYANGKNLGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKLHYTTETIKCPQPKALDEFTIIQDPQPQYQFRDYFIVTCKQGYQLMEGNQALLSFTAVCQNDGTWHRAMPRCKIKNCGQPQSLSNGDFRYITTKGVTTYEASIQYHCHEPYYKMLTRAGSSESMRGIYTCTAQGIWKNEEEGEKMPRCLPVCGKPVNPVTQKERIIRGQPARPGNFPWQAFTTTHGRGGGALLGDRWILTAAHTIYPKHHNKENDNANPKMLVFLGHTNVEQIKKLGHHPVRRVIIHPDYRQDEPNNFEGDIALLELENSVTLGPELLPICLPDNETFYGQGLMGYVSGFGITEDKLAFDLRFVRLPVADSEACQRWLQTKKDTSPFSQNMFCSGDPAVQQDACQGDSGGVFAVRDRNRDIWVATGIVSWGIGCGEGYGFYTKVLNYVDWIKKEMGDEN
-
分子量
84.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C1ra, a potent serine protease inhibitor, is critical in regulating the complement system, which plays a vital role in innate immunity and inflammation. Disruption of the complement cascade can lead to various autoimmune diseases and pathological conditions, highlighting the need for targeted therapeutic interventions. Research on recombinant C1ra protein has gained momentum due to its potential implications in managing complement-mediated disorders such as atypical hemolytic uremic syndrome and hereditary angioedema. The development of C1ra as a recombinant therapeutic agent promises to provide precise control over the complement activation pathway, allowing for improved patient outcomes. In addition, understanding the structure-function relationship of C1ra at the molecular level can facilitate the design of more effective inhibitors and enhance our overall knowledge of the complement system's complexities. With advancements in biotechnology, C1ra recombinant protein's characterization and potential applications are being extensively investigated, aiming to establish it as a cornerstone in the treatment of complement-related diseases and to unravel new therapeutic avenues.
